Chemed (CHE) Bank of America Global Healthcare Conference 2026 summary
Event summary combining transcript, slides, and related documents.
Bank of America Global Healthcare Conference 2026 summary
12 May, 2026Hospice operations and regulatory environment
Census growth outlook was raised due to improved management of referral balances and effective mitigation of the Medicare cap, especially in Florida.
Real-time metrics and targeted selling resources help balance short and long length of stay patients, supporting sustainable growth.
Proposed 2027 Medicare rate increase is 2.4% nationwide, with Florida likely seeing a lower increase near 1%.
Incremental regulatory oversight, including the Service and Spending Variation Index, is expected, with industry input ongoing.
Oversight is seen as an opportunity to gain referrals as trusted providers, provided patient access is not restricted.
Margin outlook and growth strategy
Margin expansion is driven by balancing admission sources and focusing on longer length of stay patients, reducing cost per patient.
ADC (average daily census) growth exceeded initial guidance, supporting both top-line and margin improvements.
Sustainable census growth is targeted at 8%-10%, with 6%-8% from ADC and the remainder from reimbursement.
Demographic trends, especially in Florida, support long-term growth opportunities.
Acquisition and expansion approach
Acquisition opportunities are evaluated weekly, but high valuations have limited activity; de novo expansion is preferred for efficiency.
Recent CON (certificate of need) approvals in Florida have outperformed expectations, with additional pending CONs in other states.
Staffing for new locations is managed by entering markets fully staffed, avoiding unmet expectations.
Selectivity in acquisitions is emphasized, focusing on referral networks and operational scale.
Latest events from Chemed
- VITAS outperformed, boosting guidance, while Roto-Rooter faced margin pressure and revenue decline.CHE
Q1 202628 Apr 2026 - Proxy details director elections, auditor ratification, pay-for-performance, and strong governance.CHE
Proxy filing9 Apr 2026 - 2025 revenue up 4.1%, but margins and EPS fell; 2026 outlook is for stronger growth.CHE
Q4 20257 Apr 2026 - Proxy covers director elections, auditor ratification, say-on-pay, and strong governance practices.CHE
Proxy filing6 Apr 2026 - VITAS shows strong growth and margin prospects, while Roto-Rooter faces a pivotal recovery year.CHE
Oppenheimer 36th Annual Healthcare MedTech & Services Conference19 Mar 2026 - Sustained EPS growth, Medicare cap management, and digital innovation drive robust 2024 results.CHE
BofA Securities 2025 Healthcare Conference2 Mar 2026 - Q2 2024 featured robust VITAS growth, Roto-Rooter declines, and raised full-year guidance.CHE
Q2 20242 Feb 2026 - Expecting high single-digit revenue and 10% EPS growth, with robust M&A and expansion plans.CHE
Jefferies 2024 Global Healthcare Conference31 Jan 2026 - VITAS growth offset Roto-Rooter softness, driving higher revenue and raised 2024 EPS guidance.CHE
Q3 202417 Jan 2026